June 10, 2021 – Following major growth, Genezen Inc, a cell and gene therapy Contract Development and Manufacturing Organization (CDMO), has announced the appointment of three board members: Iain Baird, Diana Caldwell and Tedd Green.
The expansion of the team comes as Genezen works to meet the increasing demand of the cell and gene therapy sector and ramp up its service offering in the manufacturing of viral vectors, including early phase process development, vector production, and analytical testing services.
Bill Vincent, Chairman and CEO of Genezen said: “I am very pleased to be welcoming Iain, Diana and Tedd to the Genezen team.
“Their skills and experience will be instrumental in helping us to build on our deep expertise in the lentiviral vector platform. They will all play a pivotal role in developing and delivering a range of differentiated services as we help customers bring life-changing therapies to market.”
Iain brings over 30 years of sector experience to Genezen, previously leading the CMC development of vaccines as well as designing and project managing biologic and CDMO facility builds in the cell and gene space. With extensive knowledge in quality and compliance, he has worked as an advisor to founders and CEOs at companies including Brammer Bio, OSO BioPharmaceuticals, and CANbridge Life Sciences.
Diana, current President, CEO and co-founder of Amplified Sciences, a start-up in-vitro diagnostics company that aims to detect and prevent disease, brings 25 years of entrepreneurial and life science experience to Genezen. After a career in marketing at Eli Lilly, she founded and was CEO of Pearl Pathways in the regulatory and quality space and has supported a number of large and small biotech companies in driving growth while adding value for customers and patients.
Tedd has over 15 years’ experience driving the success of CDMOs in the biopharmaceutical industry including roles as President of Cook Pharmica and Senior Vice President of Catalent Biologics. He co-founded and is currently COO at INCOG BioPharma Services. Tedd’s extensive leadership, finance and operational experience will be invaluable to Genzen’s ambitious growth plans.
You may also be interested in...
LVV Approaches to Pseudotyping and Plasmid…
As cell and gene therapies (C>s) continue to provide unprecedented advancements...Read more
Genezen Announces the Appointment of Steven…
BOSTON, MA and FISHERS, IN. – March 13, 2023 – Genezen,...Read more
Omar Lamm on Developments in Pharma…
An interview with Omar Lamm discussing his career in pharma, where...Read more
Understanding the requirements of viral vector…
Analytical method development, qualification, and validation are an integral part of...Read more